Join the DDA or

Emerade AAI blockage risk

Remind patients to always carry two devices

July 12th 2019

Tagged: MHRA alert

By Ailsa Colquhoun

Healthcare professionals are being asked to contact all patients and carers supplied with an Emerade adrenaline autoinjector to inform them of the risk of needle blockage with this product.

Patients should be reminded of the advice to always carry two in-date adrenaline autoinjectors with them at all times. Additional advice is to:

  • Check expiry date and replace the pen before it expires
  • Use the autoinjector at first signs of anaphylaxis
  • Call 999, ask for an ambulance and say anaphylaxis
  • Lie flat if possible with your legs up to keep your blood flowing
  • Use second pen if still unwell after 5-15 minutes

There is also a fact sheet with advice on the use of adrenaline auto-injectors which patients or carers are encouraged to read.

Bausch & Lomb UK limited has informed the MHRA that the risk of Emerade product failing to deliver a dose of adrenaline from the syringe due to blockage of the needle is higher than previously thought, affecting 2.3 in every thousand pens.

The Medicines and Healthcare products Regulatory Agency (MHRA) is not recalling batches of Emerade.  Corrected product is expected to be introduced into the market from mid-July 2019.

For all the latest news of the 2019 DDA annual conference...

Learn more